ARTICLE | Clinical News

AT2101 hyaluronic acid formulation data

September 13, 1993 7:00 AM UTC

HYALF said that its AT2101 topical pain formulation gave more intensive analgesia that lasted longer, compared to control medication, in a Phase III crossover trial in 60 patients.

In 18 patients with acute pain due to osteoarthritis of the knee with swelling, and in 17 of 19 patients with acute pain due to tender points in the trapezius muscle, there was a significantly higher measure of pain threshold (p<0.001) when the patients received diclofenac with hyaluronic acid, compared to when the same patients received the diclofenac gel alone. Two patients in the tender points group did not complete the three-week trial; six patients in the study with rheumatoid arthritis of the knee were evaluated, but the small size of this sample precluded statistical conclusions. ...